GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Acutaas Chemicals Ltd

Acutaas Chemicals Q2 FY27 PAT up 71.4% YoY to ₹1,231mn, revenue ₹4,369mn

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 27 Oct 2026, 12:59 PM IST  ·  BSE ID: b6c16ad7-4445-40b1-92cb-fdb95c36d384
View Original BSE Filing (PDF)
💡
In Simple Terms
Acutaas Chemicals' Q2 profit rose 71.4% to ₹1,231mn, with revenue up 42.7%, and a new South Korea plant opened.
🤖 AI Summary
  • Acutaas Chemicals reported Q2 FY27 Revenue from Operations at ₹4,369mn, up 42.7% YoY.
  • Quarterly Profit After Tax (PAT) stood at ₹1,231mn, marking a 71.4% increase YoY.
  • PAT Margins improved to 28.2% in Q2 FY27 compared to 23.5% in Q2 FY26.
  • Company inaugurated a new South Korea manufacturing facility for semiconductor chemicals.
  • FY27 revenue growth guidance revised upward from 25% to around 30%.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
₹4,369mn
42.7%
PAT (Q2 FY27)
₹1,231mn
71.4%
PAT Margin (Q2 FY27)
28.2%
EBITDA (Q2 FY27)
₹1,760mn
84.6%
EBITDA Margin (Q2 FY27)
40.3%
Revenue from Operations (H1 FY27)
₹7,666mn
49.3%
PAT (H1 FY27)
₹1,981mn
71.0%
🏢 How This Affects the Company
📈
Business Impact
The inauguration of a South Korea manufacturing facility positions Acutaas Chemicals to expand its presence in the semiconductor ecosystem, producing high-purity chemicals for various applications. Strong performance in Pharmaceutical Intermediates offset softer Specialty Chemicals segment results, contributing to upward revised FY27 revenue growth guidance.
💰
Financial Impact
Consolidated PAT increased by 71.4% YoY to ₹1,231mn in Q2 FY27, with PAT margins improving to 28.2%. EBITDA rose 84.6% YoY to ₹1,760mn, and EBITDA margin expanded to 40.3%, indicating enhanced profitability.
⚙️
Operational Impact
The new South Korea facility expands Acutaas Chemicals' manufacturing capabilities, specifically for advanced pharmaceutical intermediates and speciality chemicals for emerging technologies. This enhances the company's ability to capitalize on opportunities in the fast-growing semiconductor market.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results press release.
👤
Who Is Affected
Shareholders benefit from the company's strong financial performance, evidenced by the 71.4% YoY increase in Q2 FY27 PAT to ₹1,231mn and improved margins.
🔍
Management Signal
Management's decision to revise FY27 revenue growth guidance upward from 25% to around 30% and EBITDA margin guidance to 38-40% signals confidence in future business outlook and operational efficiency.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — check revenue and profit growth trends.
Updates on the utilization and contribution from South Korea facility.
Further details on the performance of Pharmaceutical Intermediates vs. Specialty Chemicals segments.
LOW RISK The filing reports strong financial results and a positive business outlook.
💡 Investor Takeaway
Acutaas Chemicals reported strong Q2 FY27 consolidated financial results, with Revenue from Operations up 42.7% YoY to ₹4,369mn and PAT increasing 71.4% YoY to ₹1,231mn. The company also inaugurated a South Korea manufacturing facility and raised its FY27 revenue growth guidance.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 Revenue from Operations increased 42.7% YoY to ₹4,369mn, demonstrating substantial top-line growth.
  • Q2 FY27 PAT rose 71.4% YoY to ₹1,231mn, with PAT margins improving to 28.2% from 23.5% in Q2 FY26.
📅 Company Track Record
Acutaas Chemicals' Q2 FY27 standalone net profit of Rs. 8,573.85 Lakhs showed a 17.63% YoY increase in previous filing. Q1 FY27 consolidated net profit was Rs. 7,497.24 lakhs, up 68.30% YoY. The company consistently reports strong YoY growth in profits.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Acutaas Chemicals' Revenue from Operations in Q2 FY27?
Acutaas Chemicals reported a Revenue from Operations of ₹4,369mn for Q2 FY27, which is a 42.7% increase compared to Q2 FY26.
What was Acutaas Chemicals' Profit After Tax (PAT) for Q2 FY27?
The Profit After Tax (PAT) for Acutaas Chemicals in Q2 FY27 was ₹1,231mn, reflecting a 71.4% year-on-year growth.
What was the EBITDA margin for Acutaas Chemicals in Q2 FY27?
Acutaas Chemicals' EBITDA margin for Q2 FY27 was 40.3%, an increase from 31.1% in Q2 FY26.
What new facility did Acutaas Chemicals inaugurate in Q2 FY27?
Acutaas Chemicals inaugurated a new manufacturing facility in South Korea, equipped to produce high-purity chemicals for the semiconductor industry.
What is Acutaas Chemicals' revised FY27 revenue growth guidance?
Acutaas Chemicals revised its FY27 revenue growth guidance upward from 25% to around 30%.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.